Factor II Activity (Prothrombin)

What Factor II Activity (Prothrombin) actually measures — the analyte, and the assay

Two entirely different tests are ordered with almost the same words, and most confusion on this page starts there. Factor II activity measures how well the clotting protein works today. The prothrombin G20210A genotype reads a single letter of DNA that never changes. One is a function, one is an inheritance, and a result for one answers nothing about the other.

Factor II is prothrombin, and prothrombin is the zymogen of thrombin. The liver makes it, and it belongs to the vitamin K-dependent family — factors II, VII, IX and X — whose glutamate residues must be carboxylated before they can bind calcium and dock onto a phospholipid surface. Without that carboxylation the protein is present and useless, which is a distinction the activity assay can see and a protein assay cannot.

The activity assay is a clotting time in disguise. Your plasma is diluted heavily into a substrate plasma that has been stripped of factor II and is otherwise complete. Whatever clotting speed the mixture then achieves must have come from your factor II. The time is read off a calibration curve built from pooled normal plasma, which is why the result is a percentage of normal and not a concentration.

Prothrombin is the most abundant clotting factor you have. It circulates at roughly 100 µg/mL — about 1.4 µmol/L for a 72 kDa protein — which is several times the concentration of factor X and orders of magnitude above factor VII. Its calcium-binding domain carries 10 gamma-carboxyglutamate residues, and every one of them has to be carboxylated by a vitamin K-dependent enzyme before the protein can dock onto a membrane. That is 10 chances for a vitamin K problem to show up as a functional deficit.

The genotype assay is a polymerase chain reaction aimed at position 20210 in the 3′ untranslated region of the F2 gene. The variant does not change the protein's sequence at all; it makes the messenger RNA processed more efficiently, so carriers run modestly more prothrombin. That is the entire mechanism, and it is why the effect size is small.

Factor II Activity (Prothrombin): what changes the blood, and what only changes the reading

What changes the prothrombin in your body:

1. Vitamin K antagonists. Warfarin blocks the recycling of vitamin K and all four dependent factors fall — but at their own half-lives. Factor VII goes first at about 6 hours; prothrombin has the longest half-life of the four, roughly 60 to 72 hours, and falls last. That lag is why an INR can look treated days before factor II actually is.
2. Liver synthetic capacity. Prothrombin is made in hepatocytes, so activity tracks synthetic function and falls in advanced liver disease.
3. Vitamin K supply. Fat malabsorption, prolonged broad-spectrum antibiotics and very low dietary intake all reduce the carboxylation step rather than the protein.
4. Consumption. Any process that generates thrombin at scale spends the zymogen faster than the liver replaces it.
5. Carrying G20210A, which raises prothrombin modestly and for life. This is the only entry on the list that a genotype explains.

What changes only the reading:

1. A direct oral anticoagulant in the sample. Every clot-based factor assay is vulnerable, because the drug inhibits the reaction the assay is timing. Dabigatran inhibits thrombin itself; the Xa inhibitors act one step upstream. Both drive a one-stage factor II activity falsely low, and the effect is dose- and timing-dependent rather than fixed Moser 2021.
2. A lupus anticoagulant. It prolongs phospholipid-dependent clotting times and therefore mimics a factor deficiency. The tell is non-parallelism: run the sample at several dilutions and a real deficiency gives the same answer each time while an inhibitor gives a rising one.
3. Heparin, usually from a line draw rather than from treatment.
4. An underfilled citrate tube. The anticoagulant volume is fixed and the blood volume is not, so a short draw over-anticoagulates the sample and prolongs every clotting time in it.
5. Hemolysis, icterus and lipemia, which interfere with optical clot detection on many analyzers — a hemolysis index above roughly 100 mg/dL of free hemoglobin is a common rejection criterion.
6. Nothing at all, if the test was the genotype. A DNA result cannot drift, cannot respond to a drug and cannot be affected by the tube. A genotype that reads differently on a second sample is an identity or labeling error and must be treated as one.

Reference interval or decision threshold — which kind of number Factor II Activity (Prothrombin) is

70–130% is a reference interval expressed against a calibrator, not against you. 100% means the pooled normal plasma this laboratory calibrated with, so the same sample can read differently in two laboratories using different pools and different reagents.

It is not a target and there is nothing to optimize. An activity of 128% is not better protected than one of 82%; both sit inside the interval of people who were measured to construct it.

The genotype is not a range at all. It is one of three categories — not present, heterozygous, homozygous — and what it needs is a penetrance figure, not a reference band.

Here is that figure, and it is smaller than the word mutation implies. In a case-control series, 7.5% of patients with venous thrombosis and 2.9% of controls carried G20210A, giving an odds ratio of 2.4 (95% CI 1.0 to 6.3); the same series found factor V Leiden in 12.2% against 1.6% Aznar 2000. A doubling of a small baseline risk is still a small risk, and most carriers never have an event.

How you would know your Factor II Activity (Prothrombin) was wrong — and when to redraw

The activity has a 60 to 72 hour half-life, and that number sets every waiting period on this page. After a vitamin K antagonist is stopped, factor II activity takes roughly 1 to 2 weeks to return — longer than the INR takes to look normal, which is exactly the trap.

Before repeating a clot-based factor II on somebody taking a direct oral anticoagulant, the drug has to be out. Two to three elimination half-lives is the minimum, which is roughly 24 to 48 hours for most agents with normal renal function and materially longer when clearance is reduced Moser 2021.

A citrate tube is 1 part anticoagulant to 9 parts blood, and the tolerance is tight. Most laboratories reject a tube filled below 90% of its draw volume, because the excess citrate binds calcium the reagent then has to replace — and at a hematocrit above 55% the plasma fraction shrinks enough that the citrate ratio has to be recalculated before any clotting time means anything.

The genotype is never repeated. Once resolved, it is resolved for life. The only reason to retest is to disprove a suspected sample mix-up.

What would have to change for the second value to mean something:

• Ask what the person was taking on the day of the draw. A low factor II in an anticoagulated sample is a pharmacology result, not a hematology one Moser 2021.
• Ask for a mixing study and a dilution series. Correction on mixing points to deficiency; failure to correct, and non-parallel dilutions, point to an inhibitor.
• Put a CMP beside it for the liver panel. A low factor II with a low albumin and a raised bilirubin is a synthetic-function picture rather than an isolated factor problem.
• Do not order the activity to answer a genetic question. Carriers of G20210A generally sit inside the ordinary activity interval; the assay cannot find them and was never meant to.

What Factor II Activity (Prothrombin) cannot tell you

It cannot detect the variant people order it for. A normal factor II activity does not exclude G20210A, and an abnormal one is almost never caused by it. If the question is inherited risk, only the genotype answers it.

The genotype cannot tell you what will happen to you, and the evidence on recurrence has moved in both directions. A prospective series of 624 patients after a documented event compared 52 heterozygous carriers with 283 patients of normal genotype and found the risk of spontaneous recurrence effectively unchanged — hazard ratio 1.3, 95% CI 0.7 to 2.3 De Stefano 2001. A 2024 meta-analysis pooling more studies did find an association — relative risk 1.60 (95% CI 1.20 to 2.14) overall and 1.79 (1.24 to 2.57) for heterozygotes — but significant only over follow-up of five years or more, not under five Wang 2024. The honest summary is a small long-run effect that a single carrier cannot act on alone.

It cannot be read without the exposure. Absolute venous thromboembolism risk across three thrombophilia strata ran 0.13, 0.35 and 0.94 per 100 woman-years overall; 0.19, 0.49 and 0.86 during combined oral contraceptive use; and 0.73, 1.97 and 7.65 during pregnancy van Vlijmen 2011. The genotype is one term in that product and not the largest one.

It cannot make a contraception decision. The authors of those absolute risks concluded that detailed counseling on options, rather than a blanket contraindication, is what the numbers support van Vlijmen 2011. That conversation belongs with a clinician who knows the rest of the history.

The wrong inference readers actually draw is that a factor II activity of 68% means a bleeding tendency. Far more often it means a citrate tube that was not filled, a line contaminated with heparin, or a direct oral anticoagulant taken that morning Moser 2021.

Sources read for these sections

• Moser KA, et al. Direct oral anticoagulant (DOAC) interference in hemostasis assays. Hematology, American Society of Hematology Education Program 2021 · PMID 34889400
• De Stefano V, et al. The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation. British Journal of Haematology 2001 · PMID 11380448
• Wang Z, et al. The association of prothrombin gene G20210A mutation with recurrent venous thromboembolism: Evidence from a meta-analysis. Annals of Vascular Surgery 2024 · PMID 39096951
• Aznar J, et al. Risk of venous thrombosis in carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives. Haematologica 2000 · PMID 11114134
• van Vlijmen EF, et al. Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception. Blood 2011 · PMID 21659542